Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: Comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT

Clinical Cancer Research

Volumn 9, Issue 10 II, 2003, Pages

  DeNardo, Sally J ^a,e   DeNardo, Gerald L ^a   Yuan, A ^a   Richman, Carol M ^a   O'Donnell, Robert T ^a   Lara, Primo N ^a   Kukis, David L ^e   Natarajan, Arutselvan ^a   Lamborn, Kathleen R ^b   Jacobs, Frederik ^f   Hartmann Siantar, Christine L ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Biomira Inc   (Canada)

^d LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M170; UNCLASSIFIED DRUG;

CALCULATION; CANCER PATIENT; CHELATION; CLINICAL ARTICLE; CONFERENCE PAPER; CONJUGATION; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOSIMETRY; DRUG BINDING; DRUG SCREENING; DRUG TOLERABILITY; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION ABSORPTION; RADIATION DEPTH DOSE; RADIATION DOSE; RADIOACTIVITY; RADIOIMMUNOTHERAPY; STATISTICAL SIGNIFICANCE;

ANTIBODIES, MONOCLONAL; CHELATING AGENTS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INDIUM RADIOISOTOPES; MALE; MODELS, CHEMICAL; PEPTIDES; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOPHARMACEUTICALS; TIME FACTORS; TISSUE DISTRIBUTION; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 12444272237     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. DeNardo, S. J., Williams, L. E., Leigh, B. R., and Wahl, R. Radioimmunotherapy: choosing an optimal dose for clinical response. Cancer (Phila.), 94 (Suppl. 4): 1275-1286, 2002.
2. 90Y-labeled anti-CD20 monoclonal antibody. Clin. Cancer Res., 5: 3281s-3286s, 1999.
3. Kaminiski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J., Fehrenbacher, L., Lister, T. A., Stagg, R. J., Tidmarsh, G. F., Kroll, S., Wahl, R. L., Knox, S. J., and Vose, J. M. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol., 19: 3918-3928, 2001.
4. Johnson, T. A., and Press, O. W. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugate the Seattle experience. Ann. Hematol., 79: 175-182, 2000.
5. Press, O. W. Radiolabeled antibody therapy of B-cell lymphomas. Semin. Oncol., 26: 58-65, 1999.
6. 90Y monoclonal antibodies 170H. 82 with autologous stem cell support and cyclosporin A. Clin. Cancer Res., 5: 3243s-3248s, 1999.
7. 111In-labeled monoclonal antitumor antibodies in normal animals and nude-mouse human tumor models. Cancer Res., 43: 5347-5355, 1983.
8. Pimm, M. V., Perkins, A. C., and Baldwin, R. W. Differences in tumor and normal tissue concentrations of iodine and indium labeled monoclonal antibody. II. Biodistribution studies in mice with human tumor xenografts. Eur. J. Nucl. Med., 11: 300-304, 1985.
9. Hnatowich, D. J. Antibody radiolabeling, problems and promises. Nucl. Med. Biol., 17: 49-55, 1990.
10. Erwin, W. D., Groch, M. W., Macey, D. J., DeNardo, G. L., DeNardo, S. J., and Shen, S. A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy. Nucl. Med. Biol., 23: 525-532, 1996.
11. Shen, S., DeNardo, G. L., Sgouros, G., O'Donnell, R. T., and DeNardo, S. J. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J. Nucl. Med., 40: 2102-2106, 1999.
12. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody (MAb) in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). Clin. Cancer Res., 5: 3292s-3303s, 1999.
13. DeNardo, G. L., Juweid, M. E., White, C. A., Wiseman, G. A., and DeNardo, S. J. Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. Crit. Rev. Oncol. Hematol., 39: 203-218, 2001.
14. Williams, L. E. Estimation of absorbed doses in radioimmunotherapy. Med. Phys., 22: 958, 1995.
15. Wiseman, G. A., Leigh, B., Erwin, W. D., Lamonica, D., Kornmehl, E., Spies, S. M., Silverman, D. H. S., Witzig, T. E., Sparks, R. B., and White, C. A. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer (Phila.), 94: 1349-1357, 2002.
16. 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin. Cancer Res., 6: 3855-3863, 2000.
17. Studer, M., Kroger, L. A., DeNardo, S. J., Kukis, D. L., and Meares, C. F. Influence of a peptide linker on biodistribution and metabolism of antibody-conjugated benzyl-EDTA. Comparison of enzymatic digestion in vitro and in vivo. Bioconjug. Chem., 3: 424-429, 1992.
18. Kukis, D. L., Novak-Hofer, I., and DeNardo, S. J. Cleavable linkers to enhance selectivity of antibody-targeted therapy of cancer. Cancer Biother. Radiopharm., 16: 457-467, 2001.
19. DeNardo, G. L., Kroger, L. A., Meares, C. F., Richman, C. M., Salako, Q. A., Shen, S., Lamborn, K. R., Peterson, J, J., Miers, L. A., Zhong, G. R., and DeNardo, S. J. Comparison of 1,4,7,10-tetraazacyclododecaine-N,N′,N″ ,N‴-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts. Clin. Cancer Res., 4: 2483-2490, 1998.
20. DeNardo, G. L., DeNardo, S. J., Peterson, J. K., Miers, L. A., Lam, K. S., Hartmann-Siantar, C., and Lamborn, K. R. Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates. Clin. Cancer Res., 9 (Suppl.): 3865s-3872s, 2003.
21. 111In-chelate conjugated anti-idiotype monoclonal antibody for radioimmunodetection of lymphoma in mice. Eur. J. Nucl. Med., 12: 455-460, 1986.
22. Deshpande, S. V., DeNardo, S. J., Meares, C. F., McCall, M. J., Adams, G. P., and DeNardo, G. L. Effect of different linkages between chelates and monoclonal antibodies on levels of radioactivity in the liver. Nucl. Med. Biol., 16: 587-597, 1989.
23. Arano, Y., Mukai, T., Uezono, T., Wakisaka K., Motonari, H., Akizawa, H., Taoka, Y., and Yokoyama, A. A biological method to evaluate bifunctional chelating agents to label antibodies with metallic radionuclides. J. Nucl. Med., 35: 890-898, 1994.
24. Quadri, S. M., Vriesendorp, H. M., Leichner, P. K.,. and Williams, J. R. Evaluation of In-111- and yttrium-90-labeled linker immunoconjugates in nude mice and dogs. J. Nucl. Med., 34., 938-945, 1993.
25. Paik, C. H., Yokoyama, K., Reynolds, J. C., Quadri, S. M., Min, C. Y., Shin, S. Y., Maloney, P. J., Larson, S. M., and Reba, R. C. Reduction of background activities by introduction of a diester linkage between antibody and a chelate in radioimmunodetection of tumor. J. Nucl. Med., 30: 1693-1701, 1989.
26. Lewis, M. R., and Shively, J. E. Maleimidocysteineamido-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions. Bioconjug. Chem., 9: 72-86, 1998.
27. Trouet, A., Masquelier, M., Baurain, R., and Deprez-De Campeneere, D. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc. Natl. Acad. Sci. USA, 79: 626-629, 1982.
28. Studer, M., and Meares, C. F. A convenient and flexible approach for introducing linkers on bifunctional chelating agents. Bioconjug. Chem., 3: 420-423, 1992.
29. Li, M., and Meares, C. F. Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates. Bioconjug. Chem., 4: 275-283, 1993.
30. DeNardo, S. J., Richman, C. M., Goldstein, D. S., Shen, S., Salako, Q. A., Kukis, D. L., Meares, C. F., Yuan, A., Welborn, J. L., and DeNardo, G. L. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Res., 17: 1735-1744, 1997.
31. 111In. Nucl. Med. Commun., 13: 11-19, 1992.
32. MacLean, G. D., McEwan, A., Noujaim, A., Hooper, H., Sykes, T. R., Bodnnar, D., Lloyd, S., and Golberg, L. Two novel monoclonal antibodies have potential for gynecologic cancer imaging. Antibody Immunoconj. Radiopharm., 4: 297-308, 1991.
33. DeNardo, S. J. Radioimmunotherapy for breast cancer: systemic tumor-targeted irradiation. Adv. Oncol., 15: 23-29, 1999.
34. Alexander, C., Villena-Heinsen, C. E., Trampert, L., Lung-Kurt, S., Oberhausen, E., Kirsch, C. M., and Schmidt, W. Radioimmunoscintigraphy of ovarian tumors with technetium-99m labelled monoclonal antibody-170: first clinical experiences. Eur. J. Nucl. Med., 22: 645-651, 1995.
35. McCall, M. J., Diril, H., and Meares, C. F. Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane. Bioconjug. Chem., 1: 222-226, 1990.
36. 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. J. Nucl. Med., 41: 952-958, 2000.
37. Penefsky, H. S. A centrifuged-column procedure for the measurement of ligand binding by beef heart Fl. Methods Enzymol., 56G: 527-530, 1979.
38. Meares, C. F., McCall, M. J., Reardan, D. T., Goodwin, D. A., Diamanti, C. I., and McTigue, M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal. Biochem. 142: 68-78, 1984.
39. DeNardo, S. J., Burke, P. A., Leigh, B. R., O'Donnell, R. T., Miers, L. A., Kroger, L. A., Goodman, S. L., Matzku, S., Jonczyk, A., Lamborn, K. R., and DeNardo, G. L. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. Cancer Biother. Radiophtrin., 15: 71-79, 2000.
40. Kukis, D. L., DeNardo, G. L., DeNardo, S. J., Mirick, G. R., Miers, L. A., Greiner, D. P., and Meares, C. F. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res., 55: 878-884, 1995.
41. Moi, M. K., Meares, C. F., and DeNardo, S. J. The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-Nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,-N′,N″, N‴-tetraacetic acid and study of its yttrium (III) complex. J. Am. Chem. Soc., 110: 6266-6267, 1988.
42. DeNardo, S. J., O'Grady, L. F., Macey, D. J., Kroger, L. A., DeNardo, G. L., Lamborn, K. R., Levy, N. B., Mills, S. L., Hellstrom, I., and Hellstrom, K. E. Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy, Int. J. Radiat. Appl. Instrum. [B], 18: 621-631, 1991.
43. Shen, S., DeNardo, G. L., DeNardo, S. J., Yuan, A., DeNardo, D. A., and Lamborn, K. R. Reproducibility of operator processing for radiation dosimetry: Nucl. Med. Biol., 24: 77-83, 1997.
44. Snyder, W. S., Ford, M. R., Warner, G. G., and Watson, S. B. "S" Absorbed Dose Per Unit Cumulated Activity for Selected Radionuclides and Organs. MIRD Pamphlet No. 11, pp. 82-83. New York: Society of Nuclear Medicine, 1975.
45. Dillman, L. T. Radionuclide Decay Schemes and Nuclear Parameters for Use in Radiation-Dose Estimation, Part 2. MIRD Pamphlet No. 6, pp. 5-32. New York: Society of Nuclear Medicine, 1970.
46. Siegel, J. A., and Stabin, M. G. Absorbed fractions for electrons and beta particles in spheres of various sizes. J. Nucl. Med., 35: 152-156, 1994.
47. Denis, L. J., Carnelro de Moura, J. L., Bono, A., Sylvester, R., Whelan, P., Newling, D., and Depauw, M. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology, 42: 119-130, 1993.
48. Goktas, S., and Crawford, E. D. Optimal hormonal therapy for advanced prostatic carcinoma. Semin. Oncol., 26: 162-173, 1999.
49. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet, 355: 1491-1498, 2000.
50. 131-labeled CC49; outcomes in patients with androgen-independent prostate cancer. Clin. Cancer Res., 4: 643-651, 1998.
51. Meredith, R. F., Bueschen, A. J., Khazaeli, M. B., Plott, W. E., Grizzle, W. E., Wheeler, R. H., Schlom, J., Russell, C. D., Liu, T., and LoBuglio, A. F. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J. Nucl. Med., 35: 1017-1022, 1994.
52. 90Y.2IT.BAD_m170 for metastatic prostate cancer. Clin. Cancer Res., 7: 1561-1568, 2001.
53. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res., 60: 6095-6100, 2000.
54. 111In-DOTA-HU-J591. J. Nucl. Med., 42: 122P-123P, 2001.
55. 188Re-anti-CEA monoclonal antibody, MN-14, in patients with gastrointestinal cancers. J. Nucl. Med., 39: 34-42, 1998.
56. Breitz, H. B., Fisher, D. R., Weiden, P. L., Durham, J. S., Ratliff, B. A., Bjorn, M. J., Beaumier, P. L., and Abrams, P. G. Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from technetium-99m-labeled antibodies and results of phase I trials. J. Nucl. Med., 34: 908-917, 1993.
57. Griffiths, G. L., Goldenberg, D. M., Diril, H., and Hansen, H. J. Technetium-99m, rhenium-186, and rhenium-188 direct-labeled antibodies. Cancer (Phila.), 73: 761-768, 1994.
58. Emami, B., Lyman, J., Brown, A., Coia, L., Goitein, M., Munzenrider, J. E., Shank, B., Solin, L. J., and Wesson, M. Tolerance of normal tissue to therapeutic radiation. Int. J. Radiat. Oncol. Biol. Phys., 21: 109-122, 1991.
59. 90Y-linked monoclonal MUC-1 antibodies. Crit. Rev. Oncol. Hematol., 38: 26-35, 2001.